POLD1 and colorectal carcinoma: So far, no studies have reported a response rate exceeding 10%.87 While the response to ICI therapy is limited for the majority of MSS CRC, hypermutated tumors with POLE/POLD1 mutations88 could represent a subgroup of MSS patients who may benefit from ICI-based therapies.